{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T22:30:57Z","timestamp":1784241057310,"version":"3.55.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.1111\/j.1743-6109.2011.02595.x","name":"ClinicalTrials.gov","doi-asserted-by":"publisher","award":["NCT00360555"],"award-info":[{"award-number":["NCT00360555"]}],"id":[{"id":"10.1111\/j.1743-6109.2011.02595.x","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,3,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Hypoactive Sexual Desire Disorder (HSDD) is characterized by low sexual desire that causes marked distress or interpersonal difficulty.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>To assess the efficacy and tolerability of flibanserin, a postsynaptic 5-HT1A agonist\/5-HT2A antagonist, in the treatment of premenopausal women with HSDD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>North American premenopausal women with HSDD (mean age 35 years) were randomized to 24 weeks\u2019 treatment with flibanserin 25 mg twice daily (N = 396), 50 mg twice daily (N = 392), 100 mg once daily at bedtime (N = 395), or placebo (N = 398).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measures<\/jats:title>\n                  <jats:p>Co-primary endpoints were changed from baseline to study end in number of satisfying sexual events (SSE) and sexual desire score, measured daily using an eDiary. Secondary endpoints included change in Female Sexual Distress Scale-Revised (FSDS-R) total score and Item 13 score (distress due to low sexual desire), Female Sexual Function Index (FSFI) total and desire domain scores, and Patient\u2019s Global Impression of Improvement.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Flibanserin 100 mg once daily was associated with an increase in SSE (P &amp;lt; 0.01 vs. placebo) but the 25 mg and 50 mg twice daily doses were not. No group showed a significant increase in eDiary desire score vs. placebo. All flibanserin regimens improved FSDS-R total, FSDS-R Item 13, FSFI total, and FSFI desire domain scores vs. placebo (P &amp;lt; 0.05, for all). More women receiving flibanserin 50 mg twice daily and 100 mg once daily considered their HSDD to have improved than women receiving placebo (44.1% and 47.0% vs. 30.3%, respectively) (P &amp;lt; 0.000, 1 vs. placebo). The most frequently reported adverse events in women receiving flibanserin were somnolence (11.8%), dizziness (10.5%), and fatigue (10.3%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In premenopausal women with HSDD, flibanserin 100 mg once daily was well tolerated and associated with statistically significant improvements in SSE, sexual desire (FSFI desire domain score but not eDiary desire score), sexual function, and decrease in sexual distress vs. placebo.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/j.1743-6109.2011.02595.x","type":"journal-article","created":{"date-parts":[[2012,1,12]],"date-time":"2012-01-12T19:32:58Z","timestamp":1326396778000},"page":"793-804","source":"Crossref","is-referenced-by-count":118,"title":["Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women: Efficacy of Flibanserin in the DAISY Study"],"prefix":"10.1093","volume":"9","author":[{"given":"John","family":"Thorp","sequence":"first","affiliation":[{"name":"University of North Carolina at Chapel Hill , Chapel Hill, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Simon","sequence":"additional","affiliation":[{"name":"George Washington University, Women\u2019s Health & Research Consultants , Washington, DC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Dattani","sequence":"additional","affiliation":[{"name":"Prairie Clinical Research Group , Saskatoon, SK , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Taylor","sequence":"additional","affiliation":[{"name":"Dean Foundation for Health Research and Education , Middleton, WI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Kimura","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharmaceuticals, Inc. , Ridgefield, CT , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Garcia Jr.","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharmaceuticals, Inc. , Ridgefield, CT , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynna","family":"Lesko","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharmaceuticals, Inc. , Ridgefield, CT , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Pyke","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharmaceuticals, Inc. , Ridgefield, CT , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,3,1]]},"reference":[{"key":"2024032600251702700_bb0010","article-title":"Diagnostic and statistical manual of mental Disorders","year":"2000","edition":"4th"},{"issue":"1","key":"2024032600251702700_bb0015","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1743-6109.2009.01619.x","article-title":"Recommendations for the clinical evaluation of men and women with sexual dysfunction","volume":"7","author":"Hatzichristou","year":"2010","journal-title":"J Sex Med"},{"key":"2024032600251702700_bb0020","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/j.1743-6109.2009.01252.x","article-title":"Correlates of sexually related personal distress in women with low sexual desire","volume":"6","author":"Rosen","year":"2009","journal-title":"J Sex Med"},{"key":"2024032600251702700_bb0025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/00224490902747222","article-title":"The dual control model: Current status and future directions","volume":"46","author":"Bancroft","year":"2009","journal-title":"J Sex Res"},{"key":"2024032600251702700_bb0030","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/j.1743-6109.2009.01309.x","article-title":"Pathways of sexual desire","volume":"6","author":"Pfaus","year":"2009","journal-title":"J Sex Med"},{"key":"2024032600251702700_bb0035","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1527-3458.2002.tb00219.x","article-title":"Pharmacology of flibanserin","volume":"8","author":"Borsini","year":"2002","journal-title":"CNS Drug Rev"},{"key":"2024032600251702700_bb0040","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1111\/j.1743-6109.2010.01938.x","article-title":"Flibanserin: Initial evidence of efficacy on sexual dysfunction, in patients with major depressive disorder","volume":"7","author":"Kennedy","year":"2010","journal-title":"J Sex Med"},{"key":"2024032600251702700_bb0045","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/cmt.4.4.267.272","article-title":"Executive summary: Stages of Reproductive Aging Workshop (STRAW)","volume":"4","author":"Soules","year":"2001","journal-title":"Climacteric"},{"key":"2024032600251702700_bb0050","article-title":"Manual for Beck Depression Inventory-II","author":"Beck","year":"1996"},{"key":"2024032600251702700_bb0055","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1743-6109.2007.00672.x","article-title":"Validation of the Female Sexual Distress Scale-Revised for assessing distress in women with hypoactive sexual desire disorder","volume":"5","author":"DeRogatis","year":"2008","journal-title":"J Sex Med"},{"key":"2024032600251702700_bb0060","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1111\/j.1743-6109.2010.02016.x","article-title":"Validation of the sexual interest and desire inventory-female (SIDI-F) in hypoactive sexual desire disorder","volume":"7","author":"Clayton","year":"2010","journal-title":"J Sex Med"},{"key":"2024032600251702700_bb0065","article-title":"Manual for Beck Scale for Suicide Ideation","author":"Beck","year":"1991"},{"key":"2024032600251702700_bb0070","author":"US Food and Drug Administration","journal-title":"Draft guidance for industry. Female Sexual Dysfunction: Clinical development of drug products for treatment"},{"key":"2024032600251702700_bb0075","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/009262300278597","article-title":"The Female Sexual Function Index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function","volume":"26","author":"Rosen","year":"2000","journal-title":"J Sex Marital Ther"},{"key":"2024032600251702700_bb0080","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/713847100","article-title":"Validation of the Female Sexual Function Index (FSFI) in women with female orgasmic disorder and in women with hypoactive sexual desire disorder","volume":"29","author":"Meston","year":"2003","journal-title":"J Sex Marital Ther"},{"key":"2024032600251702700_bb0085","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1111\/j.1743-6109.2011.02312.x","article-title":"Content validity of the Female Sexual Function Index (FSFI) in pre- and post-menopausal women with hypoactive sexual desire disorder (HSDD)","volume":"8","author":"Revicki","year":"2011","journal-title":"J Sex Med"},{"key":"2024032600251702700_bb0090","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1111\/j.1743-6109.2011.02385.x","article-title":"Does the Female Sexual Distress Scale-Revised (FSDS-R) cover the feelings of women with HSDD?","volume":"8","author":"DeRogatis","year":"2011","journal-title":"J Sex Med"},{"key":"2024032600251702700_bb0095","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/biomet\/75.4.800","article-title":"A sharper Bonferroni procedure for multiple tests of significance","volume":"75","author":"Hochberg","year":"1988","journal-title":"Biometrika"},{"key":"2024032600251702700_bb0100","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1111\/j.1743-6109.2010.01763.x","article-title":"Acute and repeated flibanserin administration in female rats modulates monoamines differentially across brain areas: A microdialysis study","volume":"7","author":"Allers","year":"2010","journal-title":"J Sex Med"},{"key":"2024032600251702700_bb0105","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1743-6109.2010.02032.x","article-title":"Multifunctional pharmacology of flibanserin: Possible mechanism of therapeutic action in hypoactive sexual desire disorder","volume":"8","author":"Stahl","year":"2011","journal-title":"J Sex Med"},{"issue":"1","key":"2024032600251702700_bb0110","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1743-6109.2009.01628.x","article-title":"Standards for clinical trials in sexual dysfunction in women: Research designs and outcomes assessment","volume":"7","author":"Clayton","year":"2010","journal-title":"J Sex Med"},{"key":"2024032600251702700_bb0115","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1111\/j.1743-6109.2008.00984.x","article-title":"Female Sexual Dysfunction, sexual distress, and compatibility with partner","volume":"5","author":"Witting","year":"2008","journal-title":"J Sex Med"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515338960?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515338960?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/9\/3\/793\/47769659\/jsm_9_3_793.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/9\/3\/793\/47769659\/jsm_9_3_793.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T01:18:41Z","timestamp":1711415921000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/9\/3\/793\/6886651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,1]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2012,3,1]]},"published-print":{"date-parts":[[2012,3,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1743-6109.2011.02595.x","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2012,3]]},"published":{"date-parts":[[2012,3,1]]}}}